Development of a SFTSV DNA vaccine that confers complete protection against lethal infection in ferrets.
Clicks: 247
ID: 17569
2019
Article Quality & Performance Metrics
Overall Quality
Not rated
Combines reader engagement with the AI quality analysis. This
article has not been analysed, so there is no overall score —
reader engagement is measured and shown alongside.
Reader Engagement
Popular Article
74.4
/100
247 views
203 readers
Trending
AI Quality Assessment
Not analyzed
Readership in this journal
PopularRanked #229 of 485 articles by views in Nature communications
Most read
Least read
Bar heights use a square-root scale. Only the 120 most-read articles are drawn; the journal has 485 in total.
Mint this article as an NFT
Not yet mintedCreate a permanent, verifiable on-chain record of this article on the Scimatic Network. The NFT is held in your Journament account, and you can withdraw it to your own wallet at any time.
5
SUSD
one-off · no wallet required
Abstract
Although the incidence of severe fever with thrombocytopenia syndrome virus (SFTSV) infection has increased from its discovery with a mortality rate of 10-20%, no effective vaccines are currently available. Here we describe the development of a SFTSV DNA vaccine, its immunogenicity, and its protective efficacy. Vaccine candidates induce both a neutralizing antibody response and multifunctional SFTSV-specific T cell response in mice and ferrets. When the vaccine efficacy is investigated in aged-ferrets that recapitulate fatal clinical symptoms, vaccinated ferrets are completely protected from lethal SFTSV challenge without developing any clinical signs. A serum transfer study reveals that anti-envelope antibodies play an important role in protective immunity. Our results suggest that Gn/Gc may be the most effective antigens for inducing protective immunity and non-envelope-specific T cell responses also can contribute to protection against SFTSV infection. This study provides important insights into the development of an effective vaccine, as well as corresponding immune parameters, to control SFTSV infection.
| Reference Key |
kwak2019developmentnature
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
|---|---|
| Authors | Kwak, Jeong-Eun;Kim, Young-Il;Park, Su-Jin;Yu, Min-Ah;Kwon, Hyeok-Il;Eo, Sukyeong;Kim, Tae-Shin;Seok, Joon;Choi, Won-Suk;Jeong, Ju Hwan;Lee, Hyojin;Cho, Youngran;Kwon, Jin Ah;Jeong, Moonsup;Maslow, Joel N;Kim, Yong-Eun;Jeon, Haili;Kim, Kee K;Shin, Eui-Cheol;Song, Min-Suk;Jung, Jae U;Choi, Young Ki;Park, Su-Hyung; |
| Journal | Nature communications |
| Year | 2019 |
| DOI |
10.1038/s41467-019-11815-4
|
| URL | |
| Keywords | Keywords not found |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.